ArticleACS omega2026
Bioluminescent Immunophage Sensors for the Quantification of Insulin.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis and then therapeutic management of diabetes require accurate, rapid monitoring of key biomarkers. Currently, only glucose levels guide diabetes management. Reliance on one biomarker can lead to diabetes misdiagnosis and improper treatment. However, adding insulin to the diagnostic portfolio could improve patient outcomes. Toward this goal, we report BLIPS (Bioluminescent Immunophage Sensor), an easy-to-produce, point-of-care immunoassay platform for the detection and quantification of insulin. BLIPS combines the highly specific detection capabilities of antibodies, ease of handling and production of phage display, and a reliable, turn-on optical signal of nanoluciferase. Specifically, fragment antigen binding (Fab) regions of an antibody sandwich pair were each genetically fused to split-nanoluciferase fragments to detect insulin via the activity of the reconstituted nanoluciferase. These constructs are too insoluble for
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.